Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Waters; GeneNews; Xagenic; and More

NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission this week, Waters said it acquired all of the outstanding stock of German gravimetric analysis systems manufacturer Rubotherm for approximately $6 million in cash. Rubotherm develops and manufactures analytical test instruments for thermogravimetric and sorption measurements. The firm said the acquisition would support and expand its thermal analysis business.

GeneNews this week reported its third quarter net loss widened to $2.8 million, or $.04 per share, from $2.2 million, or $.04 per share, in Q3 2015. The company noted that its turnaround is not yet reflected in its financial results, but said that it has a new customer, NueHealth, to kick start its population health model. The company ended the quarter with $100,000 in cash and cash equivalents.

Xagenic said this week that the beta version of its automated X1 molecular diagnostic testing system has been successfully tested at an external clinical site. The first assay developed for the system is a combined chlamydia and gonorrhea (CT/NG) test. The external study showed that the X1 system can be used as a point-of-care platform, and that the X1 CT/NG test generated results comparable to gold-standard molecular tests run at centralized labs, the company said.

The John Wayne Cancer Institute at the St. Johns Health Center announced this week that it has teamed up with Singapore-based Clearbridge BioMedics to establish a Circulating Tumor Cell Center of Research Excellence (CTC CoRE). This new center — which combines JWCI's experience in assessing CTCs in patients and Clearbridge's expertise in isolating CTCs — will be set up this month. Its initial focus will be on melanoma, followed by epithelial cancers. In the future, JWCI hopes the center will evolve into a CLIA service for testing blood biopsy samples, in order to help clinicians with diagnosis, treatment monitoring, and personalized therapies.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.